{
  "docId": "019de077-72f9-7549-be02-1cb8598bb783",
  "docSlug": "e2ad68eb257d4e7a3f142ed0c8be9c7f",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 36,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a three-column layout to summarize key strategic pillars: clinical assets, development timeline, and platform pedigree.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-72f9-7549-be02-1cb8598bb783/3",
  "deckHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783",
  "deckJsonHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783.json",
  "deckAnchorHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.215
      },
      "kind": "list",
      "text": "Conviction with Epetraborole in NTM; Near-Term Catalysts Disciplined Capital Spend; Proven Boron Based Discovery Platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ee02118-81cf-47c1-a228-6d01b82fb49c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.88,
        "x": 0.06,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "Epetraborole clinical progress, upcoming Phase 3 milestones, and Anacor-derived platform history.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "838ad34d-49a4-47e7-8bdb-e7d29c1da67f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.23,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "EBO= Epetraborole; EOP-2= End of Phase 2 meeting; ID= Infectious disease; MACRo2= Mycobacterium avium complex respiratory outcomes 2; PRO= Patient reported outcome; QOL-B= Quality of Life – Bronchiectasis; TR-MAC= Treatment-refractory Mycobacterium avium complex",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7652541d-8fc1-4a21-872f-038c5134c555",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Advancing Novel Therapies With Our Boron Chemistry Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcc78e2a-0387-4518-975c-026513e552a1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "26ffffc9-0027-4589-964a-59f6fb91d1b8",
      "evidence": "This presentation contains an executive summary with key points highlighted.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}